SMARCA4 and neoplasm: Next-generation sequencing of SMARCA4-UT has shown a high tumor mutation burden (TMB) in some cases, suggesting that regimens containing immune checkpoint inhibitors may offer promising treatment strategies.10,12) While publication bias should be taken into account, a durable response to pembrolizumab in thoracic SMARCA4-UT has been reported in a single case.13)